Clinical trial NCT04414137: Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin
Official title: Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dactinomycin Adverse Reaction
Bone and Joint Infection
Keywords: Eosinophilic pneumonia
Daptomycin
Bone and joint infection
Adverse event
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-06-04
Enrollment: 20
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients having had an eosinophilic pneumonia under daptomycine given to treat an osteoarticular infection (BJI/PJI) treated at the CRIOAc Lyon

Brief summary: Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria.

Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide.

The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future

Detailed description: Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria.

The Infectious Diseases Society of America recommends the use of daptomycin 6 mg / kg / day in the second-line treatment of IOA on staphylococcal but also enterococcal prostheses, as an alternative to vancomycin and linezolid.

In case of renal failure, daptomycin is often considered as a good therapeutic alternative to glycopeptides.

Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide. Although a large proportion of cases have been reported in patients receiving daptomycin in unapproved indications, the use of daptomycin in authorized indications has also been associated with this risk.

The dosage of daptomycin makes it possible to evaluate its effectiveness and prevent the occurrence of a overdose, provider of side effects.

The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future

Eligibility criteria: Inclusion Criteria:

* patients having had an eosinophilic pneumonia under daptomycine given to treat an osteoarticular infection (BJI/PJI)

Exclusion Criteria:

-

Primary outcomes:
measure: description of BJI/BJI in patients having eosinophilic pneumonia due to daptomycin
timeFrame: 2 months
measure: description patients having eosinophilic pneumonia due to daptomycin
timeFrame: 2 months
measure: rate of eosinophilic pneumonia due to daptomycin in osteoarticular infection: the adverse event
timeFrame: 6 months
measure: Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: dosage of daptomycine
timeFrame: 6 months
measure: Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: duration of daptomycine
timeFrame: 6 months
measure: Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: daptomycine plasma clearance
timeFrame: 6 months
measure: Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: daptomycine volume distribution
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon
Study officials:
References: